Home      Tickers | SPY | NQ100 | DOW | Global | ETFs | Sector ETFs | 3x ETFs | ETF Movers | Stock Movers | Trading Alerts
     ^  SNGX:  Intraday  Hourly  Forecast  Similar  Waves  GapOpen  Research  Timing  Gains  Losses  Strategies  Practice
     Wed. Apr. 2, 2003

Trading Signals: SNGX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Fri. Oct. 21, 2016)

(Soligenix, Inc.)

SNGX latest price $260.0000 (4.84%) ($230.0000 - $274.0000) on Wed. Apr. 2, 2003.


Trend Analysis and Forecast
 
Average Daily Percentage Swing  0% (three month average)
RSI   50
Latest Price   $260.0000(4.84%)
Stocks Behave Similarly  Similar Stock List
Daily Trend  SNGX advances 104.8% a day on average for past five trading days.
Market Behavior  Normal for large cap. Normal for small cap.
Correlated ETFs  Broad market will support SNGX advance at 0% a week (0% probability)
  OIH(9%)    EWG(6%)    IWM(6%)    QQQ(6%)    SPY(6%)  
Factors Impacting SNGX price  SNGX will advance at least -0% in a week (0% probabilities).
  TLT(-5%)    SHY(-2%)    REMX(-1%)    LQD(0%)    XLP(3%)  
Explanation   The rally is not sustainable and not supported by the broad market.
 
 
Relative Volatility   (options are extremely cheap)
 
Market Trend Strength  0% (StdDev 0%)
Hourly BBV   0 ()
Intraday Trend   5.7%
  
 

  


5 Day Moving Average  $101.6(155.91%)
10 Day Moving Average  $0(INF%)
20 Day Moving Average  $0(INF%)
To recent high  0%
To recent low  4.8%
Market Cap  $7.434b
 
 
 
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

March 23, 2020 On March 23, 2020, Soligenix, Inc. (NASDAQ:SNGX) announced an expansion of the ongoing collaboration with the University of Hawaii at Manoa to develop potential coronavirus vaccines, including one against SARS-CoV-2 to prevent COVID-19. Soligenix has performed extensive work on vaccines targeting other viruses in collaboration with the University of Hawaii, the University of Colorado, and Hawaii Biotech, Inc. That work has demonstrated efficacy in using a surface protein from other viruses (e.g., ebola), adjuvanting them, and thermostabilizing them. SARS-CoV-2, and other betacoronaviruses, have spike proteins on the surface that aids in viral entry and antibodies to that protein could prevent viral entry.

$. SNGX price fluctuates within INF% (three month std-dev: 0%) daily (68% of days).

getNextHourMoveProbability failed